Publisher's Synopsis
In persons failing INSTI-based regimens, the panel now recommends that a genotypic assay for INSTI resistance should be performed to determine whether to include a drug from this class in subsequent regimens (AII). Previously, the Panel recommended that INSTI resistance testing should be considered (BIII) in this setting.